December 12, 2025

Hormonal Changes Influence Uveitis Activity

Reproductive life stages linked to distinct uveitis activity patterns across the female lifespan

The Ophthalmologist

December 11, 2025

Managing a Diabetic Foot Infection

A small ulcer hid a limb-threatening diabetic infection, highlighting how structured, guideline-based evaluation prevents missed diagnoses in high-risk patients.

Conexiant

December 10, 2025

Optimizing Diagnostic Stewardship: The Lab Director’s Perspective

Programs that refine test ordering, performance, and reporting can reduce unnecessary treatments and enhance lab efficiency.

The Pathologist

December 09, 2025

Rainer Storb, MD, Receives Distinguished Wallace H. Coulter Award at ASH Annual Congress

The American Society of Hematology (ASH) presented the Wallace H. Coulter Award for Lifetime Achievement in Hematology to Rainer Storb, MD, during the Society’s Annual Congress held in Orlando. Dr. St...

The ASCO Post

December 09, 2025

DSCSA in Action: Real-World Lessons from US Supply Chain Implementation 

After a decade of preparation, the US pharmaceutical supply chain has seamless, serialized traceability for every prescription drug. Here are my lessons learned during that process.

The Medicine Maker

December 07, 2025

Dana-Farber Cancer Institute drives deep remissions in Waldenstrom’s with targeted, time limited therapies

Early phase results from Dana Farber suggest chemo free, time limited strategies may reduce the need for lifelong treatment in Waldenström’s

Dana-Farber

December 06, 2025

Phase III VERONA trial results show potential benefit for some groups with myelodysplastic syndrome (MDS)

Pivotal phase III VERONA trial results presented at the American Society of Hematology annual meeting show no overall survival improvement, but potential for sub-group benefit and no added side effects.

Dana-Farber

December 05, 2025

Project DISARM: New Cancer Mission Emphasizes Risk Assessment and Early Detection of Ovarian Cancer

Often referred to as a “silent killer,” ovarian cancer is the most lethal of female cancers. Issues of late detection and poor survival rates continue to persevere, leading to increasing levels of inc...

The ASCO Post

December 05, 2025

Ivonescimab, a Dual-Targeting Bispecific Antibody, Improves Progression-Free Survival in Squamous NSCLC

In the phase III HARMONi-6 trial, conducted in China, the bispecific antibody ivonescimab, given with chemotherapy, improved progression-free survival by 4.2 months over the PD-1 inhibitor tislelizuma...

The ASCO Post